Age-prioritized use of antivirals during an influenza pandemic

BackgroundThe WHO suggested that governments stockpile, as part of preparations for the next influenza pandemic, sufficient influenza antiviral drugs to treat approximately 25% of their populations. Our aim is two-fold: first, since in many countries the antiviral stockpile is well below this level, we search for suboptimal strategies based on treatment provided only to an age-dependent fraction of cases. Second, since in some countries the stockpile exceeds the suggested minimum level, we search for optimal strategies for post-exposure prophylactic treatment of close contacts of cases.MethodsWe used a stochastic, spatially structured individual-based model, considering explicit transmission in households, schools and workplaces, to simulate the spatiotemporal spread of an influenza pandemic in Italy and to evaluate the efficacy of interventions based on age-prioritized use of antivirals.ResultsOur results show that the antiviral stockpile required for treatment of cases ranges from 10% to 35% of the population for R0 in 1.4 – 3. No suboptimal strategies, based on treatment provided to an age-dependent fraction of cases, were found able to remarkably reduce both clinical attack rate and antiviral drugs needs, though they can contribute to largely reduce the excess mortality. Treatment of all cases coupled with prophylaxis provided to younger individuals is the only intervention resulting in a significant reduction of the clinical attack rate and requiring a relatively small stockpile of antivirals.ConclusionOur results strongly suggest that governments stockpile sufficient influenza antiviral drugs to treat approximately 25% of their populations, under the assumption that R0 is not much larger than 2. In countries where the number of antiviral stockpiled exceeds the suggested minimum level, providing prophylaxis to younger individuals is an option that could be taken into account in preparedness plans. In countries where the number of antivirals stockpiled is well below 25% of the population, priority should be decided based on age-specific case fatality rates. However, late detection of cases (administration of antivirals 48 hours after the clinical onset of symptoms) dramatically affects the efficacy of both treatment and prophylaxis.

[1]  Gerardo Chowell,et al.  Quantifying the transmission potential of pandemic influenza , 2007, Physics of Life Reviews.

[2]  A. Perelson,et al.  Kinetics of Influenza A Virus Infection in Humans , 2006, Journal of Virology.

[3]  A. Nizam,et al.  Containing pandemic influenza with antiviral agents. , 2004, American journal of epidemiology.

[4]  Cécile Viboud,et al.  Transmissibility and mortality impact of epidemic and pandemic influenza, with emphasis on the unusually deadly 1951 epidemic. , 2006, Vaccine.

[5]  Mark A. Miller,et al.  Synchrony, Waves, and Spatial Hierarchies in the Spread of Influenza , 2006, Science.

[6]  Stefano Merler,et al.  The Impact of the Unstructured Contacts Component in Influenza Pandemic Modeling , 2008, PloS one.

[7]  Glezen Wp,et al.  Emerging infections: pandemic influenza. , 1996, Epidemiologic reviews.

[8]  Adam Meijer,et al.  Influenza virus resistance to oseltamivir: what are the implications? , 2009, European journal of public health.

[9]  C. Furlanello,et al.  Mitigation Measures for Pandemic Influenza in Italy: An Individual Based Model Considering Different Scenarios , 2008, PloS one.

[10]  Seyed M. Moghadas,et al.  Population-Wide Emergence of Antiviral Resistance during Pandemic Influenza , 2008, PloS one.

[11]  Cécile Viboud,et al.  Trends for Influenza-related Deaths during Pandemic and Epidemic Seasons, Italy, 1969–2001 , 2007, Emerging infectious diseases.

[12]  Julien Arino,et al.  Antiviral resistance during pandemic influenza: implications for stockpiling and drug use , 2009, BMC infectious diseases.

[13]  A. Nizam,et al.  Containing Pandemic Influenza at the Source , 2005, Science.

[14]  R. Webster,et al.  Are We Ready for Pandemic Influenza? , 2003, Science.

[15]  J. Raboud,et al.  Antiviral therapy and outcomes of influenza requiring hospitalization in Ontario, Canada. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  Piero Poletti,et al.  Spontaneous behavioural changes in response to epidemics. , 2009, Journal of theoretical biology.

[17]  D. Cummings,et al.  Strategies for containing an emerging influenza pandemic in Southeast Asia , 2005, Nature.

[18]  Cécile Viboud,et al.  Epidemiologic characterization of the 1918 influenza pandemic summer wave in Copenhagen: implications for pandemic control strategies. , 2008, The Journal of infectious diseases.

[19]  Ping Yan,et al.  Emergence of drug resistance: implications for antiviral control of pandemic influenza , 2007, Proceedings of the Royal Society B: Biological Sciences.

[20]  S. Leach,et al.  Real-time epidemic forecasting for pandemic influenza , 2006, Epidemiology and Infection.

[21]  F Y Aoki,et al.  Early administration of oral oseltamivir increases the benefits of influenza treatment. , 2003, The Journal of antimicrobial chemotherapy.

[22]  D. Cummings,et al.  Strategies for mitigating an influenza pandemic , 2006, Nature.

[23]  Frederick Hayden,et al.  Developing new antiviral agents for influenza treatment: what does the future hold? , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[24]  Jürg Oliver Straub,et al.  Meeting Report: Risk Assessment of Tamiflu Use Under Pandemic Conditions , 2008, Environmental health perspectives.

[25]  R. May,et al.  Infectious Diseases of Humans: Dynamics and Control , 1991, Annals of Internal Medicine.

[26]  T. Uyeki,et al.  Influenza diagnosis and treatment in children: a review of studies on clinically useful tests and antiviral treatment for influenza , 2003, The Pediatric infectious disease journal.

[27]  M. Lipsitch,et al.  How generation intervals shape the relationship between growth rates and reproductive numbers , 2007, Proceedings of the Royal Society B: Biological Sciences.

[28]  M. Osterholm,et al.  Preparing for the next pandemic. , 2005, The New England journal of medicine.

[29]  C. Macken,et al.  Mitigation strategies for pandemic influenza in the United States. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[30]  K. Ungchusak,et al.  Severe Human Influenza Infections in Thailand: Oseltamivir Treatment and Risk Factors for Fatal Outcome , 2009, PloS one.

[31]  J. Hyman,et al.  Transmission Dynamics of the Great Influenza Pandemic of 1918 in Geneva, Switzerland: Assessing the Effects of Hypothetical Interventions , 2022 .

[32]  Glezen Wp Emerging Infections: Pandemic Influenza , 1996 .

[33]  P. Kaye Infectious diseases of humans: Dynamics and control , 1993 .

[34]  Markus Schwehm,et al.  Antiviral prophylaxis during pandemic influenza may increase drug resistance , 2009, BMC infectious diseases.

[35]  A. Osterhaus,et al.  Pre- or post-pandemic influenza vaccine? , 2007, Vaccine.

[36]  J. Robins,et al.  Transmissibility of 1918 pandemic influenza , 2004, Nature.